U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

abnormal involuntary movement

MedGen UID:
98232
•Concept ID:
C0392702
•
Disease or Syndrome
Synonyms: Abnormal involuntary movement; Abnormal involuntary movements

Definition

dyskinesia due to extrapyramidal disorder; as a general rule, symptoms are absent during sleep, reduced with relaxation, and increased with stress. [from CRISP]

Professional guidelines

PubMed

A new era in the diagnosis and treatment of tardive dyskinesia.
Caroff SN
CNS Spectr 2023 Aug;28(4):401-415. Epub 2022 Oct 24 doi: 10.1017/S1092852922000992. PMID: 36278439
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M, Pigato G, Kane JM, Correll CU
Drug Des Devel Ther 2018;12:1215-1238. Epub 2018 May 14 doi: 10.2147/DDDT.S133205. PMID: 29795977Free PMC Article
Levodopa treatment and dendritic spine pathology.
Nishijima H, Ueno T, Funamizu Y, Ueno S, Tomiyama M
Mov Disord 2018 Jul;33(6):877-888. Epub 2017 Sep 7 doi: 10.1002/mds.27172. PMID: 28880414Free PMC Article

Recent clinical studies

Etiology

Assessment and Treatment of Abnormal Involuntary Movements: A Clinically Focused Narrative Review.
Petriceks A, Vyas CM, Paudel S, Donovan AL, Van Alphen MU, Stern TA
Harv Rev Psychiatry 2024 Mar-Apr 01;32(2):47-57. doi: 10.1097/HRP.0000000000000390. PMID: 38452284
A new era in the diagnosis and treatment of tardive dyskinesia.
Caroff SN
CNS Spectr 2023 Aug;28(4):401-415. Epub 2022 Oct 24 doi: 10.1017/S1092852922000992. PMID: 36278439
Tardive dyskinesia: Out of the shadows.
Hauser RA, Truong D
J Neurol Sci 2018 Jun 15;389:1-3. Epub 2018 Feb 5 doi: 10.1016/j.jns.2018.02.009. PMID: 29449008
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH
Lancet Psychiatry 2017 Aug;4(8):595-604. Epub 2017 Jun 28 doi: 10.1016/S2215-0366(17)30236-5. PMID: 28668671
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF
Am J Psychiatry 2017 May 1;174(5):476-484. Epub 2017 Mar 21 doi: 10.1176/appi.ajp.2017.16091037. PMID: 28320223

Diagnosis

The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties.
Chouinard G, Cosci F, Chouinard VA, Alphs L
Psychother Psychosom 2023;92(6):359-366. Epub 2023 Dec 7 doi: 10.1159/000535113. PMID: 38061344
Tardive dyskinesia: Out of the shadows.
Hauser RA, Truong D
J Neurol Sci 2018 Jun 15;389:1-3. Epub 2018 Feb 5 doi: 10.1016/j.jns.2018.02.009. PMID: 29449008
Clinical management of tardive dyskinesia: Five steps to success.
Citrome L
J Neurol Sci 2017 Dec 15;383:199-204. Epub 2017 Nov 16 doi: 10.1016/j.jns.2017.11.019. PMID: 29246613
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF
Am J Psychiatry 2017 May 1;174(5):476-484. Epub 2017 Mar 21 doi: 10.1176/appi.ajp.2017.16091037. PMID: 28320223
Antipsychotic drug-induced movement disorders.
Blanchet PJ
Can J Neurol Sci 2003 Mar;30 Suppl 1:S101-7. doi: 10.1017/s0317167100003309. PMID: 12691483

Therapy

Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K
Tremor Other Hyperkinet Mov (N Y) 2024;14:13. Epub 2024 Mar 13 doi: 10.5334/tohm.842. PMID: 38497033Free PMC Article
Tardive dyskinesia: Out of the shadows.
Hauser RA, Truong D
J Neurol Sci 2018 Jun 15;389:1-3. Epub 2018 Feb 5 doi: 10.1016/j.jns.2018.02.009. PMID: 29449008
Levodopa treatment and dendritic spine pathology.
Nishijima H, Ueno T, Funamizu Y, Ueno S, Tomiyama M
Mov Disord 2018 Jul;33(6):877-888. Epub 2017 Sep 7 doi: 10.1002/mds.27172. PMID: 28880414Free PMC Article
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH
Lancet Psychiatry 2017 Aug;4(8):595-604. Epub 2017 Jun 28 doi: 10.1016/S2215-0366(17)30236-5. PMID: 28668671
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF
Am J Psychiatry 2017 May 1;174(5):476-484. Epub 2017 Mar 21 doi: 10.1176/appi.ajp.2017.16091037. PMID: 28320223

Prognosis

Regional Homogeneity in schizophrenia patients with tardive dyskinesia: a resting-state fMRI study.
Yu T, Li Y, Li N, Huang J, Fan F, Luo X, Tan S, Yang F, Tian B, Tian L, Li CR, Tan Y
Psychiatry Res Neuroimaging 2023 Oct;335:111724. Epub 2023 Oct 18 doi: 10.1016/j.pscychresns.2023.111724. PMID: 37871408
Treatment of severe tardive dyskinesia with concurrent administration of olanzapine, clonazepam, baclofen, and gabapentin: a case report.
Guo X, Chen J, Wang W, Jiang B, Liang B
J Int Med Res 2023 Oct;51(10):3000605231195154. doi: 10.1177/03000605231195154. PMID: 37812512Free PMC Article
Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia.
Caroff SN, Leong SH, Roberts CB, Berkowitz RM, Campbell EC
J Clin Psychopharmacol 2020 Jul/Aug;40(4):373-380. doi: 10.1097/JCP.0000000000001229. PMID: 32639290
Abnormal involuntary movements are linked to psychosis-risk in children and adolescents: Results of a population-based study.
Kindler J, Schultze-Lutter F, Michel C, Martz-Irngartinger A, Linder C, Schmidt SJ, Stegmayer K, Schimmelmann BG, Walther S
Schizophr Res 2016 Jul;174(1-3):58-64. Epub 2016 May 7 doi: 10.1016/j.schres.2016.04.032. PMID: 27160790
Laryngeal tardive dyskinesia.
Fève A, Angelard B, Lacau St Guily J
J Neurol 1995 Jul;242(7):455-9. doi: 10.1007/BF00873549. PMID: 7595677

Clinical prediction guides

Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K
Tremor Other Hyperkinet Mov (N Y) 2024;14:13. Epub 2024 Mar 13 doi: 10.5334/tohm.842. PMID: 38497033Free PMC Article
Clinical management of tardive dyskinesia: Five steps to success.
Citrome L
J Neurol Sci 2017 Dec 15;383:199-204. Epub 2017 Nov 16 doi: 10.1016/j.jns.2017.11.019. PMID: 29246613
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH
Lancet Psychiatry 2017 Aug;4(8):595-604. Epub 2017 Jun 28 doi: 10.1016/S2215-0366(17)30236-5. PMID: 28668671
KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF
Am J Psychiatry 2017 May 1;174(5):476-484. Epub 2017 Mar 21 doi: 10.1176/appi.ajp.2017.16091037. PMID: 28320223
Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease.
Ossig C, Antonini A, Buhmann C, Classen J, Csoti I, Falkenburger B, Schwarz M, Winkler J, Storch A
J Neural Transm (Vienna) 2016 Jan;123(1):57-64. Epub 2015 Aug 8 doi: 10.1007/s00702-015-1439-8. PMID: 26253901

Recent systematic reviews

Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review.
Golsorkhi M, Koch J, Pedouim F, Frei K, Bondariyan N, Dashtipour K
Tremor Other Hyperkinet Mov (N Y) 2024;14:13. Epub 2024 Mar 13 doi: 10.5334/tohm.842. PMID: 38497033Free PMC Article
Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
Solmi M, Pigato G, Kane JM, Correll CU
Drug Des Devel Ther 2018;12:1215-1238. Epub 2018 May 14 doi: 10.2147/DDDT.S133205. PMID: 29795977Free PMC Article
Calcium channel blockers for antipsychotic-induced tardive dyskinesia.
Essali A, Soares-Weiser K, Bergman H, Adams CE
Cochrane Database Syst Rev 2018 Mar 26;3(3):CD000206. doi: 10.1002/14651858.CD000206.pub4. PMID: 29578611Free PMC Article
Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract 2017 Nov;71(11) Epub 2017 Oct 12 doi: 10.1111/ijcp.13030. PMID: 29024264
Wearable sensor-based objective assessment of motor symptoms in Parkinson's disease.
Ossig C, Antonini A, Buhmann C, Classen J, Csoti I, Falkenburger B, Schwarz M, Winkler J, Storch A
J Neural Transm (Vienna) 2016 Jan;123(1):57-64. Epub 2015 Aug 8 doi: 10.1007/s00702-015-1439-8. PMID: 26253901

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...